Johnson & Johnson asked for help from competitors against vaccines after blood clots with its own vaccinations arose

J&J also wanted to build an informal alliance with its competitors, hoping that the industry will be able to speak with one voice about the safety of the vaccines and to address the public’s concerns about the blood clots, reports the Journal .

In a statement to CNN on Friday, a Pfizer (PFE) spokesman declined to comment on the details of the WSJ report. “Pfizer seizes opportunities for scientific exchange when we can make a meaningful contribution that is not represented by other groups or regulators,” the spokesman said. “We have and will continue to work with other vaccine makers, as appropriate, as we are all fighting this deadly pandemic.”

Modern (MRNA) and AstraZeneca (AZN) declined to comment.

Johnson & Johnson (JNJ) said in an email to CNN that “the safety of the patients who use our products is our top priority”, and that the company is actively working with the US and European authorities. The company also noted that the pandemic has led to ‘unprecedented collaboration and the sharing of information and information available to the public, and further we add’ we believe that collaborative scientific exchange can lead to more powerful answers to questions. ‘

The latest on the coronavirus pandemic and vaccines

The news comes just three days after the Centers for Disease Control and Prevention and the Food and Drug Administration recommended to suspend the use of the Johnson & Johnson vaccine, following six reported U.S. cases of a rare and serious blood clot.

All six cases were among women between 18 and 48 years old, the agencies said in a statement, and the symptoms occurred six to 13 days after vaccination. The recommendation to break comes from an ‘abundance of caution’, they added, and these cases “appear to be extremely rare.”

CNN’s Nadia Kounang contributed to this report.

.Source

Share this:

Related